Medexus Pharmaceuticals Inc. announced organizational changes designed to better position the company as it continues to integrate the transformative acquisitions of Medexus Inc. The company also announced that the board of directors of the company has appointed Ken d'Entremont as Chief Executive Officer of the company. Mr. d'Entremont joined the company as a director and Chief Operating Officer following the company's acquisition of Medexus, of which he was the founder, President, Chief Executive Officer and Chair of the board of directors. Mr. d'Entremont has over 30 years of experience in the pharmaceutical industry and will lead a strong commercial team focussed on the company's growth going forward.

Pierre Lapalme, the Chair of the Board since 2009, has determined to step down as a member of the Board effective December 19, 2018. The company also announced that effective upon Mr. Lapalme's resignation, the Board has appointed Peter van der Velden as Chair of the Board. Mr. van der Velden is the Managing General Partner of Lumira Ventures and has significant private and public market experience in the pharmaceutical industry.

Sylvain Chrétien, the founder of Pediapharm Inc., has been appointed as President of the Canadian Operations of the company. Terri Shoemaker, the President of Medac Pharma prior to its acquisition by the Company, has been appointed as President of the United States Operations of the company.